关于肿瘤患者实际治疗管理中遵循科学协会指南的信息缺乏。此项多中心前瞻性调查旨在提高对意大利医学肿瘤协会（AIOM）2017-2018建议的认识，征集了胰腺腺癌的治疗未经过的成年患者。A组接受辅助治疗，B组接受初级化疗，C组有转移性疾病。在2021年3月31日之前收集的患者结果及其随访显示：自2017年7月以来，在44个意大利中心共有923名符合条件的患者中，有833名患者参与了该研究（90％）。其中，中位年龄为69岁（范围36-89岁；24％> 75岁）；48％为女性；93％的患者的ECOG（东部合作组织肿瘤学小组）表现评分为0或1；A组：16％，B组：30％；C组：54％；72％北部，13％中部，15％南部。其中，A组指南遵从率为68％（95％置信区间[CI] 59％至76％）；53％的患者接受了吉西他滨治疗，15％的患者接受了吉西他滨+卡培他滨治疗；中位CA19.9为29（范围0-7300；15％未报告）；中位生存期为36.4个月（95％ CI 27.5-47.3个月）。B组指南遵从率为96％（95％ CI 92％至98％）；55％的患者接受了nab-紫杉醇+吉西他滨治疗，27％的患者接受了FOLFIRINOX治疗，12％的患者接受了吉西他滨治疗，3％的患者参与了临床试验；中位CA19.9为337（范围0-20220；9％未报告）；中位生存期为18.1个月（95％ CI 15.6-19.9个月）。C组指南遵从率为96％（95％ CI 94％至98％）；71％的患者接受了nab-紫杉醇+吉西他滨治疗，16％的患者接受了吉西他滨治疗，8％的患者接受了FOLFIRINOX治疗，4％的患者参与了临床试验；76％的患者报道有肝转移，23％的患者报道有肺转移；中位CA19.9值为760（范围0-1374500；9％未报告）；中位生存期为10.0个月（95％ CI 9.1-11.1个月）。GARIBALDI调查显示了遵循指南的极高比例和与文献相符的生存结果。应增强CA19.9测试；还存在未满足的营养和心理咨询需求。目前在进行加入更新后AIOM指南的遵循评估的招募工作。版权所有© 2023 Elsevier Ltd.，授权转载。

Information about the adherence to scientific societies guidelines in the 'real-world' therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative to 2017-2018 recommendations of the Italian Association of Medical Oncology (AIOM).Treatment-naive adult patients with pancreatic adenocarcinoma were enrolled. Group A received adjuvant therapy, group B received primary chemotherapy, and group C had metastatic disease. The results on patients accrued until 31 October 2019 with a mature follow-up were presented.Since July 2017, 833 eligible patients of 923 (90%) were enrolled in 44 Italian centers. The median age was 69 years (range 36-89 years; 24% >75 years); 48% were female; 93% had Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; group A: 16%, group B: 30%; group C: 54%; 72% Nord, 13% Center, 15% South. In group A, guidelines adherence was 68% [95% confidence interval (CI) 59% to 76%]; 53% of patients received gemcitabine and 15% gemcitabine + capecitabine; median CA19.9 was 29 (range 0-7300; not reported 15%); median survival was 36.4 months (95% CI 27.5-47.3 months). In group B, guidelines adherence was 96% (95% CI 92% to 98%); 55% of patients received nab-paclitaxel + gemcitabine, 27% FOLFIRINOX, 12% gemcitabine, and 3% clinical trial; median CA19.9 was 337 (range 0-20220; not reported 9%); median survival was 18.1 months (95% CI 15.6-19.9 months). In group C, guidelines adherence was 96% (95% CI 94% to 98%); 71% of patients received nab-paclitaxel + gemcitabine, 16% gemcitabine, 8% FOLFIRINOX, and 4% clinical trial; liver and lung metastases were reported in 76% and 23% of patients, respectively; median CA19.9 value was 760 (range 0-1374500; not reported 9%); median survival was 10.0 months (95% CI 9.1-11.1 months).The GARIBALDI survey shows a very high rate of adherence to guidelines and survival outcome in line with the literature. CA19.9 testing should be enhanced; nutritional and psychological counseling represent an unmet need. Enrollment to assess adherence to updated AIOM guidelines is ongoing.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.